{
    "clinical_study": {
        "@rank": "149689", 
        "arm_group": [
            {
                "arm_group_label": "Arm HFP", 
                "arm_group_type": "Experimental", 
                "description": "1st heartburn episode Intervention Hydrotalcid, 2nd heartburn episode Famotidine, 3rd heartburn episode Placebo"
            }, 
            {
                "arm_group_label": "Arm HPF", 
                "arm_group_type": "Experimental", 
                "description": "1st heartburn episode Intervention Hydrotalcid, 2nd heartburn episode Placebo, 3rd heartburn episode Famotidine"
            }, 
            {
                "arm_group_label": "Arm FHP", 
                "arm_group_type": "Experimental", 
                "description": "1st heartburn episode Intervention Famotidine, 2nd heartburn episode Hydrotalcid, 3rd heartburn episode Placebo"
            }, 
            {
                "arm_group_label": "Arm FPH", 
                "arm_group_type": "Experimental", 
                "description": "1st heartburn episode Intervention Famotidine, 2nd heartburn episode Placebo, 3rd heartburn episode Hydrotalcid"
            }, 
            {
                "arm_group_label": "Arm PHF", 
                "arm_group_type": "Experimental", 
                "description": "1st heartburn episode Intervention Placebo, 2nd heartburn episode Hydrotalcid, 3rd heartburn episode Famotidine"
            }, 
            {
                "arm_group_label": "Arm PFH", 
                "arm_group_type": "Experimental", 
                "description": "1st heartburn episode Intervention Placebo, 2nd heartburn episode Famotidine, 3rd heartburn episode Hydrotalcid"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the efficacy and safety of a single oral\n      administration of 1000 mg Talcid\u00ae (study medication), a single oral administration of 10 mg\n      famotidine and a single oral administration of placebo (comparator without an active\n      substance) in treating the symptoms of acute heartburn episodes. The study is designed to\n      collect more efficacy data on Talcid\u00ae in patients using self-medication to relief the\n      symptoms of acute heartburn."
        }, 
        "brief_title": "Placebo Controlled Phase IV Study to Compare the Efficacy and Safety of a Single Dose of Oral Talcid, a Single Dose of Oral Famotidine and a Single Dose of Placebo in Patients With Acute Heartburn Episodes", 
        "completion_date": {
            "#text": "February 2004", 
            "@type": "Actual"
        }, 
        "condition": "Heartburn", 
        "condition_browse": {
            "mesh_term": "Heartburn"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female between the age of 18 to 65 years\n\n          -  A minimum of 6 months history of heartburn\n\n          -  History of relief of heartburn episodes after self-medication (OTC use) within at\n             least 2 hours\n\n          -  Occurrence of heartburn episodes at least twice a week during the previous two months\n\n          -  Severity of heartburn episodes at least 5 on an 11-category heartburn severity scale\n\n        Exclusion Criteria:\n\n          -  History of 'alarming symptoms' e.g. weight loss, vomiting, dysphagia, anemia,\n             hematemesis or melaena\n\n          -  History of gastric ulcer or gastroesophageal reflux disease requiring regular or\n             intermittent therapy with H2-antagonists or proton pump inhibitors within the\n             previous year\n\n          -  History of significant gastrointestinal hemorrhage or gastrointestinal surgery\n\n          -  Gastrointestinal odynophagia (pain during swallowing)\n\n          -  History or concurrent known duodenitis, pyloric dysfunction with alkaline reflux,\n             motility disturbances, Heliobacter pylori gastritis, or cholelithiasis\n\n          -  Pregnant or lactating women, or sexually active women of child-bearing potential\n             unless using effective contraception"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "477", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01928888", 
            "org_study_id": "11201"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm HFP", 
                    "Arm HPF", 
                    "Arm FHP", 
                    "Arm FPH", 
                    "Arm PHF", 
                    "Arm PFH"
                ], 
                "description": "2 tablets hydrotalcite (2x500mg) 1000mg and 1 capsule placebo to famotidine", 
                "intervention_name": "Talcid (Hydrotalcite, BAY4516H)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Arm HFP", 
                    "Arm HPF", 
                    "Arm FHP", 
                    "Arm FPH", 
                    "Arm PHF", 
                    "Arm PFH"
                ], 
                "description": "2 tablets placebo to hydrotalcite and 1 capsule famotidine 10 mg", 
                "intervention_name": "Famotidine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Arm HFP", 
                    "Arm HPF", 
                    "Arm FHP", 
                    "Arm FPH", 
                    "Arm PHF", 
                    "Arm PFH"
                ], 
                "description": "2 tablets placebo to hydrotalcite and 1 capsule placebo to famotidine", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Famotidine", 
                "Hydrotalcite", 
                "Aluminum Hydroxide", 
                "Magnesium Hydroxide"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Acute heartburn episodes", 
        "lastchanged_date": "August 22, 2013", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Frankfurt", 
                        "country": "Germany", 
                        "state": "Hessen", 
                        "zip": "60596"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dresden", 
                        "country": "Germany", 
                        "state": "Sachsen", 
                        "zip": "01307"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany", 
                        "state": "Sachsen", 
                        "zip": "04107"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "ask Central Contact", 
                        "country": "Germany"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "10437"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "6", 
        "official_title": "A Randomized, Double-blind, Three-fold Cross-over, Multi-center Study to Compare the Efficacy and Safety of a Single Dose of Oral Talcid (1000 mg Hydrotalcite), a Single Dose of Oral Famotidine 10 mg, and a Single Dose of Placebo in Patients With Acute Heartburn Episodes.", 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2004", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The total heartburn relief is calculated as sum of the heartburn relief scores based on a  5-point verbal rating scale.", 
            "measure": "Total heartburn relief over 0-60 min", 
            "safety_issue": "No", 
            "time_frame": "up to 60 minutes"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01928888"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The total heartburn relief is calculated as sum of the heartburn relief scores based on a  5-point verbal rating scale.", 
                "measure": "Total heartburn relief 0-30 min after comparison hydrotalcite vs. placebo and vs famotidine", 
                "safety_issue": "No", 
                "time_frame": "up to 30 min"
            }, 
            {
                "description": "The total heartburn relief is calculated as sum of the heartburn relief scores based on a  5-point verbal rating scale.", 
                "measure": "Total heartburn relief 0-3 h after comparison hydrotalcite vs. placebo and vs famotidine", 
                "safety_issue": "No", 
                "time_frame": "up to 3 h"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2003", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}